DONATE
Drug Development Pipeline
Aztreonam (Cayston®)
Status
To PatientsTherapeutic Approach
Anti-Infective
Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with Pseudomonas aeruginosa.
Status
A Phase 3 clinical trial demonstrated improvement in lung function and respiratory symptoms for those infected with Pseudomonas aeruginosa. Cayston® received FDA approval in 2010.
Sponsor
The program was sponsored by Gilead Sciences, Inc. and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Latest News on Aztreonam
-
New Inhaled Antibiotic Cayston® Gains Rapid and Broad Acceptance – 2010 NACFC
November 15, 2010
Learn moreA key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
-
New Inhaled Antibiotic Cayston® Now Available for People with CF
March 04, 2010
Learn moreA new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
-
CF Foundation Plays Important Role in Bringing New Inhaled Antibiotic Cayston to Patients
February 22, 2010
Learn moreThe U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis (CF).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More